Special issue on Hindawi Journal
2 June 2017

Computational Approaches to Elucidate the Role of Noncoding Mutations in Cancer

Call for Papers

Over the past ten years, the advent of high-throughput technologies has allowed the sequencing of thousands of tumor samples revealing the landscape of somatic mutations in protein coding genes. However, only the more recent decreasing costs of sequencing have enabled whole-genome-sequencing (WGS) of thousands of tumors by individual research groups and efforts such as TCGA (The Cancer Genome Atlas) and ICGC (International Cancer Genome Consortium) providing the scientific community with precious resources for further investigations.

Since previously genome-wide association studies (GWASs) using DNA from nondisease cells (usually blood) have revealed that many loci that are associated with cancer susceptibility lie in noncoding regions of the genome, it is reasonable to expect that a substantial portion of the recurrent noncoding mutations observed in cancer could have a regulatory effect and drive the tumor genesis. This may be particularly for neuroblastoma and non-small cell lung cancer in which the relative paucity of coding driver mutations limits the possibility of defining cancer driver genes with high significance.

Studies of noncoding mutations are currently reserved for research purposes and have not been incorporated into precision medicine cancer care approaches in clinic. The identification of noncoding driver mutations can enable therapeutic approaches that target linked proteins and will provide noncoding germline variants associated with increased cancer susceptibility. These aspects highlight the importance of accurately i) determining driver noncoding mutations and ii) interpreting their functional effects.

i) Computational methods to annotate and prioritize potentially functional noncoding variants with high impact should be improved. In effect noncoding variants are more abundant than coding ones and diverse covariates (genomic mutation rate and/or functional activity) should be used to improve the estimate of driver noncoding mutations and to distinguish them from passengers noncoding mutations.

ii) To understand the effect of sequence variants in noncoding regions, it is important to examine the role of various noncoding functional elements. Noncoding elements can have diverse roles in the regulation of protein-coding genes. They consist of noncoding RNA and cis-regulatory regions. Noncoding RNAs (ncRNAs) act through different mechanisms to modulate gene expression and may have an important role in cancer biology. Cis-regulatory regions include promoters and distal elements (enhancers, silencers, and insulators) which regulate gene expression following binding by transcription factors (TFs). Besides TF-binding sites, other modes of cis-regulation exist in the genome. Indeed the 3'untranslated regions (3'UTR) of mRNA contain binding sites for microRNAs (miRNA) and have a role in mRNA stability and translation; the 5'UTRs contain regulatory elements for both transcription and translation stages, such as the 5'-cap structure, translation initiation motifs, and internal ribosome entry sites. Noncoding mutations affect regions that are involved in complex regulating signalling pathways as well as signal crosstalk that are characterized by numerous and diverse dynamic networks of biochemical reactions and signalling interaction between cellular components. Such complex systems can be well studied using biological network analysis in which the inherent stochastic nature of the system could be modelled and the information of functional molecular interactions from various data (high-throughput experiments) can facilitate a variety of analysis and simulation techniques.

The development of novel network and systems level approaches will be important for understanding the functional effects of noncoding mutations in a high-throughput manner, including their functional interplay. We invite researchers to submit original research articles and reviews to stimulate further work in this area.

Potential topics include but are not limited to the following:

  • Development of algorithms for delineating the driver noncoding mutations in cancer
  • Development of bioinformatics to prioritize noncoding variants and validate their functional relevance
  • Systematic analysis (both at DNA and at RNA level) of mutations in the 5'untranslated and 3'untranslated regions (UTRs) of genes and functional assessment of their effect on mRNA stability and translation. Descriptive large-scale studies are also welcome
  • Functional assessment of mutations in introns to evidence their role on the splicing efficacy or on the alternative splicing
  • Analysis of the effect of noncoding variants on epigenetic changes at regulatory elements by targeted strategies or genome-wide approaches
  • Analysis of the effect of noncoding variants on transcriptional dysregulation of noncoding RNAs (ncRNAs)
  • Functional assessment of mutations in ncRNAs to evidence their role on target regulation
  • Analysis of noncoding mutations associated with topologically associated domains (TADs) and the alteration of cancer genome architecture
  • Analysis of the interplay between germline variants and somatic variants both in coding and in noncoding regions
  • Development of network approaches to link noncoding driver mutations with the expression of the protein-coding genes they regulate and with the other elements
  • Development of new computational models to study the complex regulating signaling pathways altered by noncoding mutations in cancer
  • Methods to predict how driver noncoding mutations can affect drug-target interactions and responses to therapeutic strategies

Authors can submit their manuscripts through the Manuscript Tracking System athttps://mts.hindawi.com/submit/journals/cmmm/dnarmc/.

Manuscript Due Friday, 29 September 2017
First Round of Reviews Friday, 22 December 2017
Publication Date Friday, 16 February 2018

Lead Guest Editor

Guest Editors